{"id":57860,"date":"2024-02-27T18:05:01","date_gmt":"2024-02-27T18:05:01","guid":{"rendered":"https:\/\/medsname.com\/ketorol-dt\/"},"modified":"2026-05-01T10:49:14","modified_gmt":"2026-05-01T10:49:14","slug":"ketorol-dt","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/ketorol-dt\/","title":{"rendered":"Ketorol DT"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Ketorol DT?<\/h3>\n

Ketorol DT<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 ketorolac tromethamine 10 mg orally disintegrating tablet<\/strong> \u03b3\u03b9\u03b1 short-term<\/strong> relief of moderate to severe acute pain. Ketorolac is unusually potent for an oral NSAID and is often used as a non-opioid analgesic<\/strong> after surgery, dental procedures, renal colic, or significant soft-tissue injury. Usual dose: 10 mg every 4–6 hours with food, for a maximum of 5 days<\/strong>. Because of GI and renal risk, ketorolac is never used chronically<\/strong> — this is a short-course medicine only.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n

Ketorol DT<\/strong> is an orally disintegrating tablet (DT) containing ketorolac tromethamine 10 mg<\/strong> — the only NSAID in the world labelled solely for short-term, strong pain relief. Ketorolac’s analgesic potency is comparable to low-dose morphine for moderate pain, which has given it a particular role in post-operative, post-dental, and renal-colic care where strong analgesia is needed without the sedation, respiratory depression, or addiction risk of opioids.<\/p>\n

The orally disintegrating format dissolves on the tongue within seconds, making it useful when swallowing tablets is difficult — post-operative nausea, recent dental surgery, or heavy vomiting.<\/p>\n

What Is Ketorol DT Used For?<\/h2>\n
    \n
  • Short-term management of moderate to severe acute pain<\/strong> — post-operative, post-partum, post-dental<\/li>\n
  • Renal colic<\/strong> (kidney stone pain) — ketorolac is as effective as parenteral opioids in many studies<\/li>\n
  • Biliary colic<\/strong><\/li>\n
  • Acute musculoskeletal injury<\/strong> — severe soft-tissue trauma<\/li>\n
  • Primary dysmenorrhoea<\/strong> — severe period pain unresponsive to first-line NSAIDs<\/li>\n
  • Acute migraine<\/strong> — second-line; particularly when triptans are contraindicated<\/li>\n<\/ul>\n

    Ketorolac is not indicated for minor or chronic pain<\/strong>. Using it for conditions where paracetamol or ibuprofen would be adequate unnecessarily exposes the patient to GI and renal risk.<\/p>\n

    How Does Ketorolac Work?<\/h2>\n

    Ketorolac is a non-selective NSAID<\/strong> — it blocks both COX-1<\/strong> (which maintains stomach lining, platelet function, and kidney perfusion) and COX-2<\/strong> (which is upregulated at sites of inflammation). This broad action explains both its strong anti-inflammatory effect and its well-known gastrointestinal and renal side-effect profile.<\/p>\n

    The therapeutic chain of events is the same for every NSAID:<\/p>\n

      \n
    1. Tissue injury or inflammation releases phospholipids from cell membranes<\/li>\n
    2. Phospholipase A₂ converts them to arachidonic acid<\/li>\n
    3. Cyclooxygenase (COX-1\/COX-2) converts arachidonic acid to prostaglandins<\/strong> — the molecules responsible for pain, swelling, and fever<\/li>\n
    4. Ketorolac blocks the COX enzymes, so less prostaglandin is produced, so there is less pain and inflammation<\/li>\n<\/ol>\n

      Because prostaglandins also protect the stomach lining, regulate kidney blood flow, and influence platelet function, the same mechanism that relieves pain is also responsible for the main NSAID side effects: stomach irritation, fluid retention, high blood pressure, and (in some individuals) kidney stress.<\/p>\n

      Ketorol DT Dosing<\/h2>\n
        \n
      • \u0391\u03c0\u03cc \u03c4\u03bf \u03c3\u03c4\u03cc\u03bc\u03b1:<\/strong> 10 mg every 4–6 hours as needed, maximum 40 mg\/day<\/li>\n
      • Maximum total duration (all routes combined):<\/strong> 5 \u03b7\u03bc\u03ad\u03c1\u03b5\u03c2<\/li>\n
      • Elderly (> 65), body weight < 50 kg, or mild renal impairment:<\/strong> maximum 40 mg\/day and total duration ideally \u2264 2–3 days<\/li>\n<\/ul>\n

        Do not exceed 5 days of continuous ketorolac therapy<\/strong> in any form. The risk of GI ulcer and kidney injury rises sharply beyond this window. Transition to an alternative analgesic (ibuprofen, diclofenac, or paracetamol) after day 5.<\/p>\n

        How to take:<\/strong> place the DT tablet on the tongue, allow it to disintegrate (5–15 seconds), swallow with saliva. No water needed. Take with food or milk when possible.<\/p>\n

        \n

        GI safety — read this before the first dose.<\/strong> Every NSAID, including Ketorol DT, carries a real risk of gastritis, peptic ulcer, and upper-GI bleeding. The risk is highest in patients over 65, in those with prior ulcer disease, and in anyone also taking low-dose aspirin, corticosteroids, SSRIs, or anticoagulants. Take Ketorol DT \u03bc\u03b5 \u03c6\u03b1\u03b3\u03b7\u03c4\u03cc<\/em>, use the lowest effective dose for the shortest reasonable time<\/em>, and ask your doctor about co-prescribing a proton pump inhibitor (omeprazole, pantoprazole) if you need it for more than 2–4 weeks.<\/p>\n<\/div>\n

        Ketorolac-specific warnings:<\/strong> Because ketorolac is unusually potent per milligram, it carries a higher rate of GI ulcers, bleeds, and acute kidney injury than most other oral NSAIDs at comparable pain-relief doses. This is why the 5-day limit exists and must be observed.<\/p>\n

        Who Should Not Take Ketorol DT?<\/h2>\n
          \n
        • Known hypersensitivity to Ketorolac or any NSAID<\/li>\n
        • Active or recurrent peptic ulcer, GI bleed, or GI perforation<\/li>\n
        • Asthma, urticaria, or rhinitis precipitated by aspirin or another NSAID (“aspirin-exacerbated respiratory disease”)<\/li>\n
        • Severe heart failure (NYHA class IV)<\/li>\n
        • Severe hepatic impairment (Child–Pugh C)<\/li>\n
        • Severe renal impairment (CrCl < 30 mL\/min)<\/li>\n
        • Third trimester of pregnancy (risk of premature ductus arteriosus closure and oligohydramnios)<\/li>\n
        • Recent coronary artery bypass graft surgery (CABG) — absolute contraindication for all NSAIDs<\/li>\n<\/ul>\n

          Ketorolac-specific:<\/strong><\/p>\n

            \n
          • Suspected or actual cerebrovascular bleeding, haemorrhagic diathesis, incomplete haemostasis<\/li>\n
          • Current, recent, or high-risk GI ulcer or bleeding<\/li>\n
          • Concurrent use of other NSAIDs or aspirin<\/li>\n
          • Concurrent use of pentoxifylline or probenecid<\/li>\n
          • Volume depletion — correct first<\/li>\n
          • Labour and delivery (inhibits uterine contractions, may delay parturition)<\/li>\n
          • Paediatric use in most jurisdictions<\/li>\n<\/ul>\n

            \u039a\u03b1\u03c1\u03b4\u03b9\u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03cc\u03c2 \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf\u03c2<\/h3>\n

            All NSAIDs (except low-dose aspirin) carry some increase in the risk of heart attack and stroke, and can worsen heart failure. The risk is dose- and duration-dependent and is generally highest with COX-2 selective agents and with diclofenac. Patients with established ischaemic heart disease, peripheral arterial disease, stroke, or uncontrolled hypertension should use non-selective NSAIDs (ibuprofen or naproxen) at the lowest effective dose, or use paracetamol instead where possible.<\/p>\n

            Renal (kidney) safety<\/h3>\n

            NSAIDs reduce renal prostaglandin production, which can cause salt and water retention, raise blood pressure, and — in vulnerable patients — cause acute kidney injury. High-risk groups are the elderly, patients on ACE inhibitors\/ARBs plus diuretics (the “triple whammy”), anyone dehydrated (vomiting, diarrhoea, heat, heavy exercise), and those with pre-existing CKD. Stop the NSAID and seek medical review if you develop reduced urine output, swelling, or unexplained weight gain.<\/p>\n

            Side Effects of Ketorol DT<\/h2>\n